Experimental pill aims to ease thick heart muscle symptoms
NCT ID NCT07675668
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests an oral drug called Aom0304 in adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The study includes people with both obstructive and non-obstructive forms. Participants receive different doses of Aom0304 for 12 weeks to find the safest and most effective dose, with dose adjustments every two weeks. The goal is to see if the drug can improve symptoms and heart function without serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aom0304 (enteric coated capsule)
What this could lead to
If successful, this could point toward a new oral treatment option for hypertrophic cardiomyopathy, potentially improving exercise capacity and reducing heart blockage.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to all patients. The drug may cause side effects like reduced heart function or abnormal lab results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.